Ben Miron
@benmironmd
Oncologist fascinated by emerging technologies and therapeutics in healthcare. Views are my own.
ID: 722711827650633729
20-04-2016 09:01:41
642 Tweet
970 Followers
2,2K Following
🔥Breaking News at #ESMO2023!🔥 EV302 is changing the game, unbelievable data (HR=0.45!!!) for metastatic urothelial cancer patients, really an evolution #EV302. Terrific presentation by Tom Powles. 🙌🔬🎗️ UroToday.com OncoAlert ESMO - Eur. Oncology
Tom Powles rocks the stage with practice-changing EV302 trial with impressive OS & PFS benefit with pembro/EV vs chemotherapy! Standing ovation & cheers by 20K people, amazing news for patients! ESMO - Eur. Oncology #esmo23 OncoAlert UroToday.com awaiting Andrea Apolo, M.D. really great discussion
Love seeing our Fox Chase Cancer Center crew at #ESMO2023 #ESMO23 ! Hossein Borghaei, DO Ben Miron Namrata (Neena) Vijayvergia MD
Congrats Ben Miron on presenting tumor fraction in ctDNA as a prognostic biomarker in mUC Ryon Graf, PhD Candice Nulsen Fox Chase Cancer Center Cleveland Clinic MD Elizabeth Plimack MD FoundationOne
Grateful for the unwavering support of my mentors Toni Choueiri, MD and Eli Van Allen It was a pleasure to present part of our work with Chris Labaki Ziad Bakouny, MD, MSc Ben Miron Matthew Zibelman Elizabeth Plimack MD Check out our poster # 459 at ASCO #GU24 on Saturday!
NECTIN4 amplification predicts response to Enfortumab vedotin in mUC! It occurs frequently across solid tumors (app. 25% of mUC)➡️potential tumor-agnostic biomarker for NECTIN4-targeting therapies! Happy to share our poster K17 ASCO #GU24! Markus Eckstein OncoAlert UroToday.com
❤️ Love our Fox Chase Cancer Center home team - couldn't ask for a better crew! Some not pictured, others covering back home, many Fox Chase Cancer Center Department of Urology contributions to #GU24
We report for the 1st time therole of tumor fraction in ctDNA in pts w/ mUC in RW Foundation Medicine 👉 ass. w/ clinico-path features & rwPFS 👉prognostic biomarker 👉may help personalize tx 👉prospective trials needed ESMO - Eur. Oncology Elsevier News Cleveland Clinic MD protect-us.mimecast.com/s/jGBqCR6nEvtn…
Excellent/elegant work by Ben Miron Shilpa Gupta et al. Agree that ctDNA holds high promise in UC. Its clinical utility regarding decision making needs well-designed trials with relevant endpoints Matt Galsky Hsieh Lab Joshua Meeks Parminder singh Gavin Ha Dr. Bishoy M. Faltas Uromigos
This trial will answer several important questions- do we need to escalate therapy to get better outcomes in the highest risk patients, and can we de-escalate in those who are lower risk. Matt Galsky Andrea Apolo, M.D. Tom Powles Guru P. Sonpavde, MD Tian Zhang, MD, MHS
It‘been a while, but 🎉🔬 The 17th episode is out. The last entity we tackled was the „incarnation“ of hot/inflamed urothelial carcinomas🔥🔥🔥🔥 But what do you know about PD-L1 testing ? Today Matt Galsky presented important data of CheckMate274 at #EAU24. PD-L1 positive
Congratulations to the amazing Scott Kopetz for his AACR Waun Ki Hong Award. Eye opening listening to his presentation on Adaptive Resistance in BRAF- and KRAS-mutated #colorectalcancer #crcsm #AACR24 #AACRSSP MD Anderson Cancer Center
Hundreds of Jewish students at Columbia University just published one of the most incredible student letters I have ever read. It's not only magnificently written, but it also clearly articulates their experiences on campus for the past six months. Their letter tells the story of